These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 30997845)

  • 1. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.
    Gomez-Arteaga A; Margolskee E; Wei MT; van Besien K; Inghirami G; Horwitz S
    Leuk Lymphoma; 2019 Jul; 60(7):1626-1631. PubMed ID: 30997845
    [No Abstract]   [Full Text] [Related]  

  • 2. JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis.
    Hsu L; Armstrong AW
    J Immunol Res; 2014; 2014():283617. PubMed ID: 24883332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus.
    Tavakolpour S
    Dermatol Ther; 2018 Sep; 31(5):e12696. PubMed ID: 30207045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapy.
    Hanna DM; Fellowes A; Vedururu R; Mechinaud F; Hansford JR
    Haematologica; 2014 Sep; 99(9):e156-8. PubMed ID: 24837469
    [No Abstract]   [Full Text] [Related]  

  • 5. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease.
    Lescoat A; Lelong M; Jeljeli M; Piquet-Pellorce C; Morzadec C; Ballerie A; Jouneau S; Jego P; Vernhet L; Batteux F; Fardel O; Lecureur V
    Biochem Pharmacol; 2020 Aug; 178():114103. PubMed ID: 32562787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.
    Liu LY; Strassner JP; Refat MA; Harris JE; King BA
    J Am Acad Dermatol; 2017 Oct; 77(4):675-682.e1. PubMed ID: 28823882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic eosinophilic leukemia with a novel JAK1 mutation responds well to the JAK1/2 inhibitor ruxolitinib.
    Wei Q; Xu J
    Blood; 2024 Jul; 144(2):238. PubMed ID: 38990537
    [No Abstract]   [Full Text] [Related]  

  • 8. Real-world clinical efficacy of tofacitinib in moderate-to-severe ulcerative colitis.
    Lopes SR; Martins C; Teixeira M; Tomás D
    World J Gastroenterol; 2024 Sep; 30(34):3929-3931. PubMed ID: 39350781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The off-label uses profile of tofacitinib in systemic rheumatic diseases.
    Zhao Z; Ye C; Dong L
    Int Immunopharmacol; 2020 Jun; 83():106480. PubMed ID: 32283509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata.
    Dai Z; Chen J; Chang Y; Christiano AM
    JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33830087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.
    Degryse S; de Bock CE; Cox L; Demeyer S; Gielen O; Mentens N; Jacobs K; Geerdens E; Gianfelici V; Hulselmans G; Fiers M; Aerts S; Meijerink JP; Tousseyn T; Cools J
    Blood; 2014 Nov; 124(20):3092-100. PubMed ID: 25193870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.
    Herbaux C; Kornauth C; Poulain S; Chong SJF; Collins MC; Valentin R; Hackett L; Tournilhac O; Lemonnier F; Dupuis J; Daniel A; Tomowiak C; Laribi K; Renaud L; Roos-Weil D; Rossi C; Van Den Neste E; Leyronnas C; Merabet F; Malfuson JV; Tiab M; Ysebaert L; Ng S; Morschhauser F; Staber PB; Davids MS
    Blood; 2021 Jun; 137(25):3495-3506. PubMed ID: 33598678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.
    Craiglow BG; King BA
    JAMA Dermatol; 2015 Oct; 151(10):1110-2. PubMed ID: 26107994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial response to venetoclax and ruxolitinib combination in a case of refractory T-prolymphocytic leukemia.
    Brothers J; Castillo DR; Jeon WJ; Joung B; Linhares Y
    Hematology; 2023 Dec; 28(1):2237342. PubMed ID: 37485976
    [No Abstract]   [Full Text] [Related]  

  • 15. [Bendamustine and tofacitinib treatment of T-cell prolymphocytic leukemia: a case report].
    Deng YF; Qian XL; Xu Y; Yang X; Yuan HJ
    Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):411-412. PubMed ID: 38951074
    [No Abstract]   [Full Text] [Related]  

  • 16. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.
    Telliez JB; Dowty ME; Wang L; Jussif J; Lin T; Li L; Moy E; Balbo P; Li W; Zhao Y; Crouse K; Dickinson C; Symanowicz P; Hegen M; Banker ME; Vincent F; Unwalla R; Liang S; Gilbert AM; Brown MF; Hayward M; Montgomery J; Yang X; Bauman J; Trujillo JI; Casimiro-Garcia A; Vajdos FF; Leung L; Geoghegan KF; Quazi A; Xuan D; Jones L; Hett E; Wright K; Clark JD; Thorarensen A
    ACS Chem Biol; 2016 Dec; 11(12):3442-3451. PubMed ID: 27791347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure of tofacitinib to achieve an objective response in a
    Wong J; Wall M; Corboy GP; Taubenheim N; Gregory GP; Opat S; Shortt J
    Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32843425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib.
    King B; Lee AI; Choi J
    J Invest Dermatol; 2017 Apr; 137(4):951-954. PubMed ID: 27887955
    [No Abstract]   [Full Text] [Related]  

  • 19. Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata.
    Gordon SC; Abudu M; Zancanaro P; Ko JM; Rosmarin D
    J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):e156-e157. PubMed ID: 30520145
    [No Abstract]   [Full Text] [Related]  

  • 20. Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors.
    Springuel L; Hornakova T; Losdyck E; Lambert F; Leroy E; Constantinescu SN; Flex E; Tartaglia M; Knoops L; Renauld JC
    Blood; 2014 Dec; 124(26):3924-31. PubMed ID: 25352124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.